<i>In vivo</i> dose response and efficacy of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against the <i>Acinetobacter baumannii-calcoaceticus</i> complex.

ABSTRACT: Multi-drug resistant (MDR) Acinetobacter baumannii is emerging as a pathogen of increasing prevalence and concern. Infections associated with this Gram-negative pathogen are often associated with increased morbidity and mortality and few therapeutic options. The β-lactamase inhibitor sulbactam used commonly in combination with ampicillin demonstrates intrinsic antibacterial activity against A. baumannii acting as an inhibitor of PBP1 and PBP3, which participate in cell wall biosynthesis. The production of β-lactamases, particularly class D oxacillinases, however, has limited the utility of sulbactam resorting to increased doses and the need for alternate therapies. Durlobactam is a non-β-lactam β-lactamase inhibitor that demonstrates broad β-lactamase inhibition including cla

SUBMITTER: O'Donnell J 

PROVIDER: S-EPMC10777848 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature